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Objectives: Variation in antibiotic use may reflect inappropriate use. We aimed to systematically describe the
variation in measures for antibiotic use among settings or providers. This study was conducted as part of the in-
novative medicines initiative (IMI)-funded international project DRIVE-AB.
Methods: We searched for studies published in MEDLINE from January 2004 to January 2015 reporting variation
in measures for systemic antibiotic use (e.g. DDDs) in inpatient and outpatient settings. The ratio between a
study’s reported maximum and minimum values of a given measure [maximum:minimum ratio (MMR)] was cal-
culated as a measure of variation. Similar measures were grouped into categories and when possible the overall
median ratio and IQR were calculated.
Results: One hundred and forty-three studies were included, of which 85 (59.4%) were conducted in Europe and
12 (8.4%) in low- to middle-income countries. Most studies described the variation in the quantity of antibiotic
use in the inpatient setting (81/143, 56.6%), especially among hospitals (41/81, 50.6%). The most frequent meas-
ure was DDDs with different denominators, reported in 23/81 (28.4%) inpatient studies and in 28/62 (45.2%) out-
patient studies. For this measure, we found a median MMR of 3.7 (IQR 2.6–5.0) in 4 studies reporting antibiotic
use in ICUs in DDDs/1000 patient-days and a median MMR of 2.3 (IQR 1.5–3.2) in 18 studies reporting outpatient
antibiotic use in DDDs/1000 inhabitant-days. Substantial variation was also identified in other measures.
Conclusions: Our review confirms the large variation in antibiotic use even across similar settings and providers.
Data from low- and middle-income countries are under-represented. Further studies should try to better eluci-
date reasons for the observed variation to facilitate interventions that reduce unwarranted practice variation.
In addition, the heterogeneity of reported measures clearly shows that there is need for standardization.
Introduction
Variation in healthcare delivery among different geographical
areas, healthcare facilities and individual providers is a nearly ubi-
quitous finding that can only be partly explained by differences in
patient characteristics or disease epidemiology.1,2 The importance
of systematically studying the extent of this variation and its
underlying causes in order to improve quality and resource utiliza-
tion was first recognized in the 1970s by Wennberg and
Gittelsohn,3 when they analysed ‘small area variations’ of hospital-
ization rates and surgical procedures in the US state of Vermont.
With the continuing emergence and spread of MDR organisms
across the globe in recent years, there has been increasing interest
in medical practice variation regarding antibiotics since inappropri-
ate use is one of the key drivers of antimicrobial resistance.4–8
Indeed, important variation in antibiotic use has been described
among countries, hospitals and physicians that share many simi-
larities in their patient populations and economic, geographical
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and epidemiological characteristics.9,10 While the exact relation-
ship between antibiotic use and emergence and spread of anti-
microbial resistance (AMR) is complex, there is, for example, a clear
correlation between a country’s level of outpatient antibiotic use
and the prevalence of certain antibiotic-resistant bacteria.11,12
Describing and ultimately understanding the variation in antibiotic
use could help to target the implementation of interventions to im-
prove antibiotic prescribing where this is most needed. Having a
clear picture of the observed variation in measures for antibiotic
use is also important to establish benchmarks for antibiotic use
measures.13
This systematic review of the literature was conducted as part
of the European DRIVE-AB project and its primary objective was to
describe the variation in use of antibiotics in outpatient and inpa-
tient settings.1 Further systematic reviews in the context of DRIVE-
AB aimed to specifically assess the definition of responsible use of
antibiotics14 and to assess quantity metrics and quality indicators
for antimicrobial use in the inpatient15,16 and outpatient
settings.17,18
Methods
This systematic review is reported following the PRISMA statement.19
Eligibility criteria
We conducted a systematic review of the published literature to identify
English language studies that describe the naturally observed variation (i.e.
the variation occurring outside the context of a specific interventional
study) in measures of systemic antibiotic use for treatment and prophylaxis
within and among different settings (e.g. countries, hospitals, hospital
units) and providers (e.g. general practitioners, paediatricians, physicians
with different specialties) at a given point in time. We included studies
describing variation in both paediatric and adult populations. Only studies
describing variation among a minimum number of providers or settings
were included (Table 1). We predefined different limits for larger entities
(such as hospitals and countries) and individual providers (Table 1). The cut-
offs were chosen for pragmatic reasons, since we felt that otherwise the
number of eligible studies would be too vast without offering much add-
itional information about variation due to the small number of entities.
We allowed the inclusion of ESAC/ESAC-net (European Surveillance of
Antimicrobial Consumption Network) studies reporting data from the same
year(s) only when the number of countries participating in the studies was
different or the described measures were different.
We tried to group similar measures into categories reflecting:
• The quantity of antibiotic use [e.g. DDDs, days of therapy (DOT), length
of therapy (LOT) with different denominators or percentage of treated
patients].
• Prescribing strategies (e.g. percentage of delayed prescriptions, per-
centage of antibiotics prescribed as empirical treatment).
• Compliance with guidelines (percentage of appropriate or compliant
prescriptions, percentage of patients treated with antibiotics within a
given timeframe).
• Process and structural measures for antibiotic stewardship policies (e.g.
percentage of prescriptions documented in the medical file, presence
of antibiotic stewardship guidelines).
• Antibiotic use for medical or surgical prophylaxis (e.g. percentage of pa-
tients receiving surgical prophylaxis for .24 h).
We excluded the following studies:
• Studies describing exclusively the use of antivirals, antifungals, anti-
mycobacterials, antiparasitic drugs and topical antibiotics.
• Studies only describing variation of antibiotic use over time within the
same setting.
• Studies only describing variation in outcomes associated with antibiotic
use (e.g. variation in rates of Clostridium difficile infection).
• Studies focusing on the variation in healthcare professionals’ views, be-
liefs, attitudes and knowledge.
• Studies describing self-reported (by patients, caregivers and physicians)
behaviours regarding antibiotic use.
• Studies whose full text could not be retrieved from any of the libraries
of the participating centres (eight different catalogues).
• Studies that presented data only graphically (no efforts were made to
contact authors).
• Interventional studies without extractable pre-intervention data.
• Systematic reviews and meta-analyses and studies not reporting ori-
ginal data (narrative reviews, opinion pieces etc.). Their reference lists
were, however, screened to identify potentially eligible studies.
Search and information sources
We searched the MEDLINE database using the PubMed interface using a
combination of search terms for the concepts (i) ‘antibiotics’, (ii) ‘quality’
and ‘quantity of use’ and (iii) ‘variation’ (for the detailed search strategy see
Table 1. Minimum number of providers or settings considered for study eligibility
Setting Unit/hospital/region/country level Provider level
Inpatient Data from5 hospitals irrespective of their size 20 providers in the same hospital
OR
Data from5 identical units (e.g. ICUs, haematology wards etc.) from
5 hospitals irrespective of their size
OR
Data from5 units/wards in the same hospital irrespective of their size
Outpatient 2 countries, regions or districts (same or different country) 50 providers in the same
geographical areaOR
5 clinics/primary health care facilities
The cut-offs were chosen for pragmatic reasons, since we felt that otherwise the number of eligible studies would be too vast without offering much
information about variation due to the small number of entities.
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Table S1, available as Supplementary data available at JAC Online). Owing
to the large number of potentially eligible studies (.6000) we used the
PubMed filters for species (‘humans’) and language (‘English’). Since we
were mostly interested in recent findings, we restricted the timeframe to
articles whose last year of data collection was 2004 (included) or later with
a publication date between 1 January 2004 and 15 January 2015.
Study selection and data collection process
All the steps of this systematic review were carried out using the Distiller
SRV
R
software (Evidence Partners, Ottawa, Canada). Duplicates were
removed before title and abstract screening using the algorithm provided
by Distiller SRV
R
. One reviewer (V. Z.) screened all titles and abstracts. A se-
cond reviewer (B. H.) independently screened a random subset of 700 ab-
stracts (13%). For 3/700 (0.4%) references screened by both reviewers
there was disagreement regarding inclusion/exclusion. All three references
were later excluded at full-text screening level.
All full-text assessments were performed by one reviewer (V. Z.) and, in
case of uncertainty, discussed with another investigator (B. H.) until a con-
sensus was reached. Data extraction was performed by one reviewer (V. Z.)
using a standardized data extraction form; any uncertainty about extracted
data was discussed with another investigator (B. H.).
Data regarding authors, setting (inpatients or outpatients), country/re-
gion, last year of data collection, study design, level of variation (providers,
units, hospitals etc.), number and characteristics of participants, data
source, category of the numerator and denominator of the measure, full
description of the measure, mean or median (as available in the text) and
measure of variability (maximum–minimum range, IQR or SD as presented
in the text) were collected (for definitions see Table S2). We extracted data
for overall antibiotic use and if the study also reported variation for specific
antibiotic classes we extracted data only for b-lactams, quinolones and
macrolides (except if the study described variation of only specific antibiotic
classes but no overall antibiotic use) since we felt that extracting data for all
individual classes would go beyond the scope of this review. Since we
mainly included observational studies and the aim of this review was to de-
scribe variation (without causal inferences) we decided not to perform risk
of bias assessment for the included studies.
Synthesis of results and summary measures
Using the search strategy (Table S1), we identified 5204 studies. After title
and abstract screening 628 studies were retained for full-text review; of
these 143 met the inclusion criteria (Figure 1). Selected study characteris-
tics are presented in Table 2. Detailed information for all 143 studies is avail-
able in Tables S5 to S8. The results of our search are presented by setting
(inpatients versus outpatients) and country income level (high versus low
to middle income using the World Bank 2015 classification20); for high-
income countries we further differentiated between European and North
Number of studies in 
MEDLINE: 5220
No additional papers 
identified through manual 
review of references of 
systematic reviews and 
meta-analyses 
16 duplicates removed 
References (title 
and abstract) 
screened: 
5204
700 abstracts randomly 
reviewed by 2nd reviewer 
3 inclusion/exclusion 
conflicts (excluded after full 
text screening) 
Excluded references* 4576
*Some studies could have >1 exclusion criterion 
Not about systemic use of antibiotics (including animal use 
and microbiological or pharmacological studies) 2139 
Not about variation among settings or providers 1647
Inappropriate publication type: 489 
Data before 2004: 297 
About beliefs/knowledge/self-reported prescribers
behaviours: 267
Insufficient number of participants (based on Table 1): 215 
Not about metrics of systemic use of antibiotics: 242  
Studies describing only variation over time: 172
Full-text references 
assessed for eligibility: 
628
Excluded references*: 485
*Some studies could have >1 exclusion criterion 
Not about variation among settings or providers: 466  
Data before 2004: 53
Inappropriate publication type: 40 
About beliefs/knowledge/self-reported prescribers 
behaviours: 37
Unable to obtain full text: 11 
Not about systemic use of antibiotics (including basic 
research): 8
Not about metrics of systemic use of antibiotics: 4
Included 
references:
143
Figure 1. Flow chart of study selection.
Variation in antibiotic use: a systematic review JAC
vi19
D
ow
nloaded from
 https://academ
ic.oup.com
/jac/article-abstract/73/suppl_6/vi17/5033626 by guest on 18 O
ctober 2018
American studies since these were the most represented regions. Data re-
garding measures for antibiotic use in paediatric patients are presented as
a separate category. Measures were extracted from each study and a
measure’s category was attributed to each of them. The complete list of
measure categories is reported in Table S3.
Given our broad search strategy, we identified a wide range of different
antibiotic use measures, often applying to specific medical conditions
(e.g. otitis media, urinary tract infections or community-acquired pneumo-
nia) or settings (e.g. ICUs, neonatal ICUs, emergency departments). In add-
ition, most studies presented only aggregated data, making it challenging
to summarize variation in a standardized way. In the absence of better al-
ternatives, we decided, whenever possible, to report the extent of variation
in a given antibiotic use measure for each study by calculating the ratio be-
tween the reported maximum and minimum value of the measure (MMR).
For example, in a study describing variation in overall antibiotic use among
hospitals in DDDs we divided the maximum value by the minimum value of
DDDs. This ratio was then used to calculate the median and IQR ratio when-
ever measures of the same category could be grouped together.
Results
Overall a total of 44 unique measures grouped in five categories
were identified (Table S3). For the purpose of this review the term
‘unique measures’ is used to indicate distinctive measures, mean-
ing measures different from one another with respect to their nu-
merator (e.g. DDDs, DOT, percentage of treated patients).
Measures that have the same numerator but different denomin-
ators, e.g. DDDs per inpatient day or per admission, were not con-
sidered unique measures for the purpose of this review because
the numerator is the same. An overview of the frequency of the
measures in the different categories both in the in- and outpatient
settings is presented in Table S4.
In the context of this review we identified 10 unique measures
for quantity, 5 for prescribing strategies, 8 for compliance with
guidelines, 18 for process and structural measures of antibiotic
stewardship policies and 3 for antibiotic prophylaxis.
Inpatient setting (81 studies)
High-income countries
Overall, 75 studies (75/143, 52.4%) met inclusion criteria for this
setting: 47 from Europe, 17 from the USA and Canada, 3 from
Australia, 1 from Israel, 1 from Japan and 6 from more than one
WHO region (see Table S2 for the definition of WHO regions).
Thirty-eight unique measures were extracted for this setting with
sometimes different studies reporting identical measures. Overall,
169 ‘non-unique’ measures reporting data about variation (also
called ‘variation data’ in this review) were represented for this
setting.
The most frequent measures concerned ‘quantity’ of antibiotic
use, with 91 variation data extracted from 58 studies. The three
most frequent unique measures (out of the 10 belonging to this
category) were DDDs (reported 34 times for overall use or for spe-
cific antibiotic classes and medical conditions and with different
denominators), followed by ‘percentage of treated patients’ (re-
ported 31 times in different settings and for different health condi-
tions) and DOT (reported 13 times both for overall and specific
antibiotic classes use and for specific medical indications and with
different denominators).Ta
b
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Table 3. Most frequent measures, Europe and North America: inpatient setting (64 studies)
Measure
Number of
studies (%)
MMR (IQR)
(if applicable) Comments
Europe
percentage of patients
treated with antibiotics
(any condition)
19/47 (40.4) Hospitals
(5 studies29–33):
median MMR 2.1
(1.8–2.4)
29PPS in 30 Finnish hospitals in 2005
30PPS to determine the prevalence of antibiotic use for hospital-acquired
infections in 393 French non-teaching hospitals in 2001 and 2006
31PPS of nosocomial infections in 41 Dutch hospitals in 2007 and 2008
32PPS to determine the prevalence and the appropriateness of antimicro-
bial use in 19 Dutch hospitals in 2008 and 2009
33ESAC PPS of antibacterial use in 20 European hospitals in 2006
LTCFs
(6 studies34–39):
median MMR 13.6
(8.9–16.5)
34Cross-sectional study in 18 nursing homes in Franche-Comte´ (France) on
residents receiving antibiotics on the study day in 2012
35PPS in 30 nursing homes in Northern Ireland in 2011
36PPS in 85 nursing homes in 15 European countries and two UK adminis-
trations in 2009
37Two PPSs in 30 nursing homes in Northern Ireland in 2009
38PPS in 9 Finnish nursing homes in 2010
39PPS in 323 nursing homes in 21 European countries in 2009
total DDDs/1000
patient-days
16/47 (34.0) Hospitals
(6 studies40–45):
median MMR 4.2
(2.3–8.1)
40Cohort study of inpatient antibacterial use in acute hospitals in England
analysed over 5 years (2008–13)
41Ecological study in French healthcare facilities
42Study on antibiotic consumption in 57 Swiss hospitals
43–45Studies on antibiotic consumption in French hospitals
ICUs
(4 studies42,46–48):
median MMR 3.7
(IQR 2.6–5.0)
42Antibiotic use data from 14 Swiss ICUs
42Antibiotic use data from 98 German ICUs
43Antibiotic use data from 10 French ICUs
44Antibiotic use data from 44 Hungarian ICUs
all measures related to
antibiotic stewardship
7/4749–55 (14.9) NA Examples of measures: presence of a surveillance system for antibiotic
usage or presence of an antibiotic stewardship programme for LTCFs
percentage of appropriate
prescriptions
1/47 (2.1) Emergency depart-
ments (1 study56):
MMR 1.5
56Appropriate antibiotic prescriptions for urinary tract infections in emer-
gency departments of 10 hospitals from different Spanish regions
antibiotic days/patient-days 2/47 (4.2) Hospitals (1 study55):
MMR 2.1
55In this study, antibiotic use was measured using number of use-days/
100 patient-days during a 7 day period. The study reported the preva-
lence of patients receiving at least two antimicrobials during the study
day in 30 Finnish hospitals
number of antibiotics
accounting for 75%
of total consumption
1/47 (2.1) Hospitals (1 study57):
MMR 2.1
57Drug utilization 75% (DU75%) in 17 European hospitals: results from the
ESAC-2 Hospital Care Sub Project
percentage of combination
therapy
1/47 (2.1) Countries (1 study58):
MMR 1.2
58European Surveillance of Antimicrobial Consumption (ESAC): value of a
PPS of antimicrobial use across Europe. The use of combination therapy
was related to hospital type, with teaching and tertiary hospitals having
a significantly higher use of combination therapy
percentage of surgical
prophylaxis .24 h
1/47 (2.1) Countries (1 study59):
MMR 3.1
59Prolonged perioperative surgical prophylaxis within European hospitals.
For the purpose of the study data were extracted from the ECDC PPS
2011–12 report
percentage of patients
receiving prophylaxis
(medical or surgical)
4/47 (8.5) LTCFs (2 studies):
MMR 22 (over-
all60), MMR 55 (for
UTI61)
56Variation was described among 44 Norwegian LTCFs. 10% of residents
on the day of the survey were receiving antibiotics for infection preven-
tion and 6% for infection treatment. The indication for prophylaxis was
UTI in all but 1 case
Hospitals (2 studies):
MMR 4.5,62 MMR
1.662,63
62Timely prophylaxis before surgery (within 1 h of procedure)
63Percentage of patients receiving prophylaxis before cystoscopy across
hospitals in different countries (data from the Global Prevalence Study
on Infections in urology)
Continued
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Europe
Forty-seven studies (47/143, 32.9%), including 9 ESAC studies,
were included for the inpatient setting, reporting data from 13 dif-
ferent European countries. We identified 18 variation data specific-
ally addressing the paediatric population and 4 variation data
concerning antibiotic prophylaxis.
Included studies described variation either among acute care
hospitals (18/47, 38.3%), long-term care facilities (LTCFs) (7/47,
14.9%), neonatal ICUs (2/47, 4.3%), adult ICUs (6/47, 12.8%), dif-
ferent hospital units (10/47, 21.3%) or different countries (4/47,
8.5%). No study described variation among providers (e.g. phys-
icians with different specialties). Concerning the nine ESAC studies,
almost all (8/9, 88.9%) addressed antibiotic use for treatment in
the adult population, describing variation among hospitals (3/9,
33.3%), units (2/9, 22.2%), LTCFs (2/9, 22.2%) or countries (2/9,
22.2%). Both among units and among LTCFs, the most frequently
reported measure was overall percentage of patients treated with
an antibiotic (only one study specifically addressed nosocomial in-
fections at the unit level).
We identified 58 variation data for this setting for the category
‘quantity’ of antibiotic use from 37 studies (Table S5) for the com-
plete list of measures with calculated levels of variation (MMR).
MMRs for the most frequently reported measures referring to the
same population, medical condition and setting are presented in
Table 3. The highest MMR for this setting was described among
LTCFs (six studies) for the measure ‘percentage of patients treated
with antibiotics for any condition’, with a median MMR of 13.3 (IQR
8.9–16.5). The same measure presented a median MMR of 2.1 (IQR
1.8–2.4) among hospitals (five studies). We also found a median
MMR of 4.2 (IQR 2.3–8.1) among hospitals (six studies) and of 3.7
(IQR 2.6–5.0) among ICUs (four studies) for the measure DDDs/
1000 patient-days.
North America
We found 17 North American studies that fulfilled inclusion criteria
for the inpatient setting: 14 from the USA and 3 from Canada; 53%
(9/17) addressed the paediatric population and 2 described vari-
ation in measures for antibiotic use in LTCFs. Three studies included
measures for antibiotic prophylaxis. One was an interventional
study. The four most frequent unique measures described for this
setting are reported in Table 3. Among the paediatric studies
the MMR for the measure ‘percentage of febrile neonates treated
Table 3. Continued
Measure
Number of
studies (%)
MMR (IQR)
(if applicable) Comments
percentage of patients
whose antibiotic prophy-
laxis was stopped ,24 h
after surgery
1/47 (2.1) Departments
(1 study64):
MMR 1.2
60The measure specifically referred to duration of surgical prophylaxis
,24 h in Scottish acute care hospitals
North America
percentage of patients
treated with antibiotics
2/17 (11.8) Departments
(1 study address-
ing adults65):
MMR 26.6
65One-day prevalence surveys conducted in acute care hospitals in 10 US
states between May and September 2011. Minimum rates correspond to
nursery wards and maximum rates to surgical critical care units
66This study examined the relationship between nursing home prescriber
adherence to the Loeb minimum criteriaa and antibiotic prescribing
rates, overall and for each of three specific conditions (urinary tract infec-
tions, respiratory infections, and skin and soft tissue infections)
LTCFs (1 study66):
MMR 4.5
DOT/antibiotic days 6/17 (35.3) Hospitals (1 study67):
MMR 1.8
67Variation was measured among 70 US academic centres
prophylaxis use before
surgery
3/17 (17.6) Hospitals (3 studies):
adults62 median
MMR 4.5
62Percentage of patients receiving prophylaxis within 1 h before surgery
DDDs/10000 patient-days 1/17 (5.9) Hospitals (1 study68):
MMR 2.5
68Interventional study examining the effect of antibiotic stewardship pro-
gramme (ASP)-based strategies (all including a component of audit and
feedback) on antibiotic consumption of target antibiotics (piperacillin/
tazobactam, fluoroquinolones, or cefepime) Data refer to the baseline
data in the intervention group (non-target antibiotics)
percentage of patients
whose antibiotic prophy-
laxis was stopped ,24 h
after surgery
Hospitals (1 study62):
MMR 4.5
62The measure specifically referred to duration of prophylaxis ,24 h across
295 US hospital groups (a hospital group comprises all hospitals sharing
identical categories for location by state, teaching status, bed size and
urban/rural location)
PPS, point prevalence study.
aThe Loeb minimum criteria, developed by a 2001 consensus conference, are minimum standards for initiation of antibiotics in long-term care set-
tings, intended to reduce inappropriate prescribing.
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with antibiotics’ among departments was 1.321 and 1.522 in two
studies, respectively.
An MMR of 2.5 was described in one study describing the same
measure in children with bronchiolitis presenting at the emergency
department. As in Europe, the MMR among LTCFs for the percent-
age of patients receiving antibiotics was high (4.5 in one study).
Low- to middle-income countries
We found three different measures described for this setting
(Table 4), two belonging to the category ‘quantity’ (DDDs and per-
centage of treated patients) and one belonging to the category
‘compliance with guidelines’ (percentage of appropriate/inappro-
priate prescription).
Six studies could be included for this setting (three of which
were from the Western Pacific WHO region); one was an interna-
tional study that included countries from more than one WHO re-
gion and the others were from four different countries. No study
included data collected after 2011. Three studies addressed the
paediatric population. Variation was mainly described among hos-
pitals (four studies, 66.7%) with an MMR of 2.1 (IQR 2–2.2) for the
measure ‘percentage of patients treated with antibiotics’ (three
studies) and an MMR of 5.1 for the measure DDDs/100 bed-days
(one study). The complete list of included studies for this setting is
presented in Table S6.
Outpatient setting (62 studies)
High-income countries
Overall, 56 studies (56/143, 39.2%) met the inclusion criteria for
this setting: 38 from Europe, 10 from the USA and Canada, 1 each
from Bahrain, Israel, Saudi Arabia and South Korea and 4 from
more than one WHO region. Overall, 110 variation data were iden-
tified (Table S7).
As for the inpatient setting, the category with the highest num-
ber of included measures was ‘quantity’ of antibiotic use, with
53 studies reporting 91 variation data. The three most frequent
measures were: (i) DDDs (34 variation data in 28 studies); (ii) per-
centage of antibiotic prescriptions for different medical conditions,
populations (e.g. children, adults or elderly people) and sometimes
for specific antibiotic classes (18 variation data in 10 studies); and
(iii) percentage of treated patients (17 variation data in 12 studies).
Europe
We included 38 studies (38/56, 67.8%) for this setting, including
15 ESAC studies. No study reported data collected after 2011. More
than half were international studies (20/38, 52.6%); the rest were
single-country studies from nine different countries. Italy was the
country with the highest number of studies (6/38, 15.8%) followed
by France (4/38, 10.5%).
Most of the studies reported variation among countries (15/38,
39.5%) or geographical areas within the same country (e.g. re-
gions, provinces, districts) (7/38, 18.4%). Ten studies (26.3%) re-
ported variation among providers and six among outpatient
clinics. Overall, most studies (36/38, 94.7%) included measures for
the category ‘quantity’ of antibiotic use, with the three most repre-
sented measures being: (i) DDDs (reported in 21 studies); (ii) per-
centage of treated patients (reported in 10 studies); and
(iii) percentage of antibiotic prescriptions (reported in 9 studies).
The second category in terms of frequency of measures was ‘pre-
scribing strategies’ [e.g. percentage of delayed prescriptions for
lower respiratory tract infections (LRTIs), days of delay before tak-
ing the antibiotic for LRTIs, percentage of patients treated with
specific antibiotic classes for respiratory tract infections, and per-
centage of antibiotics administered through parenteral route] with
10 unique measures included followed by ‘compliance with guide-
lines’ (e.g. percentage of guideline-compliant prescriptions for
LRTIs) with 6 unique measures included. No study reporting meas-
ures for the category ‘process and structural measures for antibi-
otic stewardship policies’ was identified for this setting.
In Table 5 we report the level of variation for the most frequent
measures: DDDs/1000 inhabitant-days, which showed a median
MMR of 3.2 (IQR 3.0–3.5) among countries (eight studies) and a
median MMR of 1.5 (IQR 1.4–1.5) among geographical areas (three
studies). For the measure ‘percentage of treated patients’ we
found an MMR of 1.4 in two studies reporting variation among geo-
graphical areas in the same country.
North America
Ten studies (10/62, 16.1% of all studies included for the outpatient
setting) describing variation in outpatient antibiotic use in North
America were identified: 6 from Canada, 3 from the USA and 1 that
included data from both countries. Two studies (20%) included
measures addressing the paediatric population. No study
described measures for antibiotic prophylaxis.
Nine studies included measures for the category ‘quantity’ of
antibiotic use and one study included one measure for the cat-
egory ‘process and structural measures for antibiotic stewardship
policies’. No study described measures for the remaining three cat-
egories (‘compliance with guidelines’, ‘prescribing strategies’ and
‘antibiotic prophylaxis’).
Table 4. Inpatient setting: low- to middle-income countries (six studies)
Measure Number of studies (%)
MMR, median (IQR)
(if applicable) Comments
DDDs/100 bed-days 3/6 (50%) Hospitals (1 study):
adults69! 5.1
69International study taking place in
.1 WHO region
Percentage of treated
patients
3/6 (50%) Hospitals (2 studies70,71):
1.9,67 2.368
70,71Both studies were from the Western pacific WHO
region (Vietnam and China)
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The most frequent measure reported for this setting (Table 5)
was DDDs/1000 inhabitant-days (six studies), with an MMR of 1.9
among geographical areas (two studies). An MMR of 1.4 was
described also for the measure ‘percentage of treated patients’,
again among geographical areas in the same country (one study).
Low- to middle-income countries
Six studies fulfilled the inclusion criteria (9.7% of all studies
included for the outpatient setting). One was an international
study and the rest were single-country studies from three different
countries (China, Iran and India). One interventional study was
Table 5. Outpatient setting: Europe and North America (48 studies)
Measure
Number of
studies (%)
MMR (maximum/minimum ratio)
(IQR) (if applicable) Comments
Europe
DDDs/1000
inhabitant-days
19/38 (50.0) Countries (8 studies6,10,72–77):
median MMR 3.2 (3.0–3.5)
Geographical areas (3 studies78–80):
median MMR 1.5 (1.4–1.5)
No study included data collected after 2009
8 were ESAC studies
percentage of treated
patients
12/38 (31.6) Geographical areas (2 studies81,82):
MMR 1.4
81The study reported the same measure twice for health dis-
tricts and local health units
82The study reported the same measure for different age
groups
percentage of total
antibiotic use
1/38 (2.6) Providers (1 study83) 83Specific focus on fluoroquinolone use
duration of therapy 1/38 (2.6) Providers (1 study84):
MMR 6
84Antibiotic use for CAP among 94 Italian GPs
percentage of compliant
prescriptions
1/38 (2.6) Clinics (1 study85):
MMR 6.6
85Antibiotic use for LRTI among GPs in 14 primary care re-
search networks in 13 European countries (GRACE study)
percentage of delayed
prescriptions
1/38 (2.6) Clinics (1 study86):
MMR 165.5
86Antibiotic use for LRTI among GPs in 14 primary care re-
search networks in 13 European countries (GRACE study)
North America
DDDs/1000
inhabitant-days
6/10 (60) Geographical areas (2 studies87,88):
MMR 1.9
87Population-level data were obtained on all outpatient oral
antibiotic prescriptions dispensed within 1 Canadian prov-
ince (British Columbia)
88Variation in outpatient oral antimicrobial use patterns
among Canadian provinces
prescriptions 2/10 (20.0) Geographical areas (1 study89):
MMR 1.4
89Data on oral antibiotic prescriptions dispensed during 2010
in the USA extracted from a national administrative
database
percentage of treated
patients
2/10 (20.0) Providers (1 study90):
MMR 2.3
90Data on antibiotic use for patients with acute otitis externa
among providers in different clinical specialties (otolaryn-
gologists, emergency departments physicians, paediatri-
cians) in the USA
percentage of non-
compliant
prescriptions
1/10 (10.0) Clinics (1 study91):
MMR 2
91Data on inappropriate use of systemic antibiotics for chil-
dren with otitis media with effusion among 19 clinics in
the USA
number of antibiotics
whose prescription is
restricted and requires
specific information
confirming the diag-
nosis in order for the
patient to be reim-
bursed by the health
system
1/10 (10.0) Geographical areas (1 study92):
MMR 15
92The objective of this study was to assess whether the rela-
tive flexibility/stringency of provincial antibiotic formula-
ries had a statistical impact upon provincial prescription
volume in Canadaa
GPs, general practitioners.
aIn Canada, provinces have the option to list antibiotics as either ‘general benefits’ (available to all by prescription) or as ‘restricted benefit’ (requiring
additional information and/or paperwork before prescriptions may be reimbursed). For example, Quebec has only one antibiotic, linezolid, in its for-
mulary that is listed as ‘restricted benefit’ while Saskatchewan has 15 restricted antibiotics in its formulary.
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included. No study included data collected after 2010. Variation
was described among providers (two studies), countries
or smaller geographical areas within the same country (two
studies) or outpatient clinics (two studies). We identified three
different measures for this setting (Table 6), with the highest
MMR (20.5) described among providers (one study) for the
measure ‘percentage of treated patients’ in a study from Iran.
The complete list of included studies for this setting is presented
in Table S8.
Measures for antibiotic use for antibiotic prophylaxis
and in the paediatric population
Nine studies including measures related to antibiotic prophylaxis
were also included (6.3%), all of them from high-income countries,
mainly from Europe and North America (six studies, 66.7%); three
studies were from more than one WHO region. Six studies focused
on perioperative prophylaxis (of which two included measures spe-
cifically addressing the paediatric population and one focused on
specific surgical procedures: prostate biopsy and cystoscopy) and
three studies focused on prophylaxis of urinary tract infections
(UTIs) in LTCFs. Three studies (one paediatric) included measures
related to compliance with antibiotic prophylaxis guidelines (e.g.
percentage of patients given prophylaxis for a duration of ,24 h).
Variation was described among hospitals (four studies), units (one
study), countries (one study) and LTCFs (three studies). The highest
MMR was found for the measure ‘percentage of patients receiving
prophylaxis’ for UTIs among LTCFs (55 in one study). Twenty-six
studies reported measures for antibiotic use in children mainly for
the inpatient setting (19/26, 73.1%). Four studies were from low-
to middle-income countries. Most of the measures belonged to
the category ‘quantity’ of antibiotic use (18/26, 69.2%), two meas-
ures (from one study) belonged to the category ‘prescribing strat-
egies’ [e.g. percentage of antibiotics prescribed as empirical
treatment for community-acquired pneumonia (CAP)] and four
(from two studies) were measures specifically addressing antibi-
otic prophylaxis. No measure for the category ‘process and struc-
tural measures for antibiotic stewardship policies’ was included.
The highest MMRs were described for the measure ‘percentage of
treated patients’ (median MMR 3.5, IQR 2.5–4.4, among hospitals
in four studies and an MMR of 4.7 in one study describing variation
among clinics) and for the measure DOT, with an MMR of 5.1
among departments in one study (Table S9).
Discussion
The most important finding of this review was the large variation
in measures of antibiotic use even across similar settings and pro-
viders. This finding was confirmed also for specific medical condi-
tions and populations both in high- and low- to middle-income
countries. A second key finding is the large heterogeneity of re-
ported measures (even without taking into account differences in
data sources; e.g. antibiotic dispensing versus administration
data), clearly indicating the need for standardization.
Most of the findings of this review concerned evaluation of the
quantity of antibiotic consumption, and variation was observed
whatever the type of measure used and regardless of the setting.
For example, for the European inpatient setting we found high vari-
ation in DDDs/1000 patient-days with a median MMR of 4.2 for
hospitals (six studies) and 3.7 for ICUs (four studies). In low- to
middle-income countries the same measure showed an MMR of
5.1 (one study) among hospitals. Variation was also observed for
antibiotic prescribing strategies, guideline compliance and for ex-
istence of antimicrobial stewardship policies across healthcare
facilities. In most of the cases measures referred to antibiotic use
for treatment in the adult population, whereas studies including
antibiotic use for prophylaxis or addressing the paediatric popula-
tion were a minority. It was not surprising to see that most of the
Table 6. Low- to middle-income countries: outpatient setting (6 studies)
Measure
Number of studies
(%)
MMR, median (IQR) (if
applicable) Comments
Percentage of
treated patients
3/6 (50) Providers (1 study93): 20.5
Clinics (1 study94): 1.4
Geographical areas
(1 study95): 1.4
93Antibiotic use among GPs and specialist physicians in Iran (this survey
was conducted on a total of almost 8 million prescriptions)
94Surveillance of antibiotic encounters carried out using a repeated cross-
sectional design for 2 years in Vellore, South India. Variation was
described among 30 health facilities
95Antibiotic use in rural areas of 10 Chinese provinces
DDDs/1000
inhabitant-days
2/6 (33.3) (one of
the studies con-
cerned the paedi-
atric population)
Countries (1 study96): 2.4 96Antibiotic use in eight Latin American countries (we considered only
data from 2007)
Percentage of
antibiotics per
prescription
1/6 (16.7) Providers (1 study97): 2.2 97Cluster randomized controlled trial of 159 GPs working in 6 cities, in 2 re-
gions in East Azerbaijan in Iran. The cities were matched and randomly
divided into an intervention arm, for an outcome-based education on
rational prescribing, and a control arm for a traditional CME programme
on the same topic. GPs’ prescribing behaviour was assessed 9 months
before and 3 months after the CME programmes
CME, continuing medical education; GPs, general practitioners.
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information retrieved from the literature came from observational
retrospective studies from high-income countries, especially from
Europe, and that data from resource-limited settings were under-
represented in the literature.23
Despite the fact that our search was performed at the begin-
ning of 2015, most data were from before 2012, most likely re-
flecting the delay between data collection, data analysis and final
publication. The great variety of measures made it difficult to sum-
marize and present the observed variation. The ratio between
maximum and minimum values is certainly a suboptimal measure
of variation since it is heavily influenced by outliers and the charac-
teristics of the measure (e.g. MMRs will be inherently different for
measures with an absolute upper and lower boundary, such as
those expressed in percentages, and measures that only have an
absolute lower boundary, such as DDDs).
Inferences on the causes of the described variation were
beyond the scope of this review. Indeed, few of the examined
studies offered clear evidence for the reasons behind the observed
variation. It seems clear, however, that much of the observed vari-
ation is ‘unwarranted’, in the sense that it is unlikely to be driven by
differences in the epidemiology of infectious diseases or patient
characteristics but could rather be explained by one or more of the
seven determinants of healthcare professionals’ behaviours
described by Flottorp et al.24 and that could also be applied to anti-
biotic prescribing practices. These seven domains are: (i) guideline
factors (e.g. guideline characteristics or presence of contradictory
guidelines); (ii) individual prescriber preferences (which could be
influenced by many factors, such as lack of agreement with spe-
cific guidelines, lack of motivation or inertia of previous practices
etc.); (iii) patient factors (e.g. patient’s expectations, inability to rec-
oncile patient’s preferences with guideline recommendations); (iv)
professional interactions (e.g. leadership, key individuals, team
processes); (v) incentives and resources (e.g. economic incentives,
technical knowledge, organizational size); (vi) capacity for organ-
izational change (e.g. planning, engaging, executing and evaluat-
ing); and (vii) social, political and legal medical norms (e.g.
legislation or regulations, priority on societal agenda, corruption,
political stability etc.). The impact of combinations of these deter-
minants on antibiotic use has been previously described in both
the inpatient and the outpatient setting.25–28
In particular in the inpatient setting, differences in ‘culture’
(country level, e.g. ideas about health, causes of disease, labelling
of illness, coping strategies and ‘treatment modalities’ differ across
countries), ‘context’ (hospital level, influenced by organizational
policies, multi-professional care-delivery system) and ‘behaviour’
(professional level) have all been described.28 In the outpatient
setting, socio-cultural differences as well as specific regulatory
practices have been associated with varying levels of prescriptions
for frequent medical conditions, such as LRTIs.27
Strengths of this review include a broad search strategy and the
inclusion of studies from a variety of different settings. There are,
however, also several limitations to our work. We only searched
the MEDLINE database over a 10 year period and we did not ex-
plore other sources of information, such as relevant surveillance
websites or single-country data. Another limiting factor is that we
did not perform a quality assessment of included studies and we
did not explore the relationship between extent of variation in
measures and outcomes of antibiotic use, e.g. resistance, costs or
rates of C. difficile infections. Although we included a large variety
of measures described in the literature, we did not address possible
benchmarks for the measures and we did not try to explore rea-
sons for the observed variation as most studies did not provide in-
formation regarding this issue. We did not address the relevance
of the measures for appropriate use. This is addressed in other
work of the DRIVE-AB consortium.14–18
Conclusions
At a time when major stakeholders are trying to find effective solu-
tions to the problem of antibiotic resistance, the large variation in
measures of antibiotic use (even across similar settings/providers
or for similar clinical conditions) remains poorly understood and
can only be partly explained by different patients’ and physicians’
attitudes. Although variation is not something negative by defin-
ition and is ‘natural’ up to a certain level, a better understanding of
this phenomenon, addressing similarities and differences across
specific settings and providers, should be pursued. Furthermore, in
order to make informative comparisons among settings, there is
need to standardize the measures used to measure the quantity
and quality of antibiotic use.
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